The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment

J. Turpin, C. Ling, E. J. Crosby, Z. C. Hartman, A. M. Simond, L. A. Chodosh, J. P. Rennhack, E. R. Andrechek, J. Ozcelik, M. Hallett, Gordon Mills, R. D. Cardiff, Joe Gray, O. L. Griffith, W. J. Muller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20–30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2ΔEx16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2ΔEx16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2ΔEx16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2ΔEx16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2ΔEx16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2ΔEx16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.129.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - May 9 2016

Fingerprint

Tumor Microenvironment
Breast Neoplasms
Proto-Oncogenes
Keratins
Neoplasms
Neoplastic Stem Cells
Dimerization
Human Mammary Glands
Oncogenes
Transcriptome
Transgenic Mice
Publications
Molecular Biology
Exons
Protein Isoforms
Breast
Transcription Factors
Epithelium
Neoplasm Metastasis
Mutation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Turpin, J., Ling, C., Crosby, E. J., Hartman, Z. C., Simond, A. M., Chodosh, L. A., ... Muller, W. J. (Accepted/In press). The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene. https://doi.org/10.1038/onc.2016.129

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. / Turpin, J.; Ling, C.; Crosby, E. J.; Hartman, Z. C.; Simond, A. M.; Chodosh, L. A.; Rennhack, J. P.; Andrechek, E. R.; Ozcelik, J.; Hallett, M.; Mills, Gordon; Cardiff, R. D.; Gray, Joe; Griffith, O. L.; Muller, W. J.

In: Oncogene, 09.05.2016.

Research output: Contribution to journalArticle

Turpin, J, Ling, C, Crosby, EJ, Hartman, ZC, Simond, AM, Chodosh, LA, Rennhack, JP, Andrechek, ER, Ozcelik, J, Hallett, M, Mills, G, Cardiff, RD, Gray, J, Griffith, OL & Muller, WJ 2016, 'The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment', Oncogene. https://doi.org/10.1038/onc.2016.129
Turpin, J. ; Ling, C. ; Crosby, E. J. ; Hartman, Z. C. ; Simond, A. M. ; Chodosh, L. A. ; Rennhack, J. P. ; Andrechek, E. R. ; Ozcelik, J. ; Hallett, M. ; Mills, Gordon ; Cardiff, R. D. ; Gray, Joe ; Griffith, O. L. ; Muller, W. J. / The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. In: Oncogene. 2016.
@article{9a2dff993ca847f19d77a3eb561ca660,
title = "The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment",
abstract = "Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20–30{\%} human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2ΔEx16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2ΔEx16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2ΔEx16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2ΔEx16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2ΔEx16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2ΔEx16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.129.",
author = "J. Turpin and C. Ling and Crosby, {E. J.} and Hartman, {Z. C.} and Simond, {A. M.} and Chodosh, {L. A.} and Rennhack, {J. P.} and Andrechek, {E. R.} and J. Ozcelik and M. Hallett and Gordon Mills and Cardiff, {R. D.} and Joe Gray and Griffith, {O. L.} and Muller, {W. J.}",
year = "2016",
month = "5",
day = "9",
doi = "10.1038/onc.2016.129",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment

AU - Turpin, J.

AU - Ling, C.

AU - Crosby, E. J.

AU - Hartman, Z. C.

AU - Simond, A. M.

AU - Chodosh, L. A.

AU - Rennhack, J. P.

AU - Andrechek, E. R.

AU - Ozcelik, J.

AU - Hallett, M.

AU - Mills, Gordon

AU - Cardiff, R. D.

AU - Gray, Joe

AU - Griffith, O. L.

AU - Muller, W. J.

PY - 2016/5/9

Y1 - 2016/5/9

N2 - Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20–30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2ΔEx16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2ΔEx16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2ΔEx16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2ΔEx16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2ΔEx16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2ΔEx16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.129.

AB - Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20–30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2ΔEx16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2ΔEx16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2ΔEx16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2ΔEx16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2ΔEx16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2ΔEx16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.129.

UR - http://www.scopus.com/inward/record.url?scp=84966521979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966521979&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.129

DO - 10.1038/onc.2016.129

M3 - Article

C2 - 27157621

AN - SCOPUS:84966521979

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -